MARKET

BNTC

BNTC

Benitec Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.950
+0.200
+5.33%
Opening 12:53 02/24 EST
OPEN
3.840
PREV CLOSE
3.750
HIGH
4.270
LOW
3.700
VOLUME
760.69K
TURNOVER
--
52 WEEK HIGH
17.39
52 WEEK LOW
2.520
MARKET CAP
17.93M
P/E (TTM)
-0.0244
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Benitec Biopharma's Gene Therapy For Rare Muscle Disorder Shows Encouraging Action In Animal Studies
Benzinga · 3h ago
Benitec Biopharma posts BB-301 genetic disorder pilot dosing study interim results
Benitec Biopharma (BNTC) announces results of the interim analysis of the BB-301 Pilot Dosing Study for the treatment of Oculopharyngeal Muscular Dystrophy ((OPMD)), a chronic, life-threatening genetic disorder.Shares of the company
Seekingalpha · 3h ago
BRIEF-Benitec Biopharma Announces Successful Results From The Interim Analysis Of The BB-301 Pilot Dosing Study
reuters.com · 4h ago
Benitec Biopharma Announces Results From Interim Analysis Of BB-301 Pilot Dosing Study
Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study HAYWARD, Calif., Feb. 24, 2021 /PRNewswire/ -- Highlights from the Interim Analysis: Biologically
Benzinga · 4h ago
Benitec Biopharma Files Shelf for Up to $75 Million in Securities
MT Newswires · 5d ago
BRIEF-Benitec Biopharma Files For Mixed Shelf Of Upto $75 Mln
reuters.com · 5d ago
WaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology
--Highlights Concerning Interlocks That Still Exist Among Current and Recently-Departed Board Members
BusinessWire · 12/08/2020 11:00
WaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology
--Highlights Concerning Interlocks That Still Exist Among Current and Recently-Departed Board Members
BusinessWire · 12/08/2020 11:00
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTC. Analyze the recent business situations of Benitec Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNTC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 483.96K
% Owned: 10.66%
Shares Outstanding: 4.54M
TypeInstitutionsShares
Increased
1
21
New
6
280.16K
Decreased
1
21.78K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.65%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Director
Jerel Banks
Chief Executive Officer/Secretary
Gregory West
Chief Financial Officer
Bryan Dulhunty
Chief Scientific Officer
Michael Graham
Secretary
Oliver Kidd
Director
Kevin Buchi
Non-Executive Director
Megan Boston
Non-Executive Director
Peter Francis
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.002929
06/01/2018
About BNTC
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Webull offers kinds of Benitec Biopharma Inc stock information, including NASDAQ:BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.